What AbGenics Life Sciences does
Founded in 2010, AbGenics Life Sciences operates in Health Tech offering antibody discovery solutions through three formats: Camelid heavy chain fragments, human scFv, and mouse scFv. The company uses antibody fragment libraries to target infectious diseases and cancers, isolating hits for further therapeutic and diagnostic development. AbGenics is also developing two new technologies, VHH-Antimicrobial peptide conjugates for addressing antimicrobial resistance and an ultrasensitive diagnostic test for detecting blood-borne pathogens in sepsis patients, especially neonates.
Who runs it
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about AbGenics Life Sciences yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.